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Novelty and Impact:  Ovarian clear cell carcinoma (OCCC) is an aggressive form of ovarian 
cancer and accounts for 5–25% of epithelial ovarian cancers. Worse treatment outcomes for 
OCCC have been attributed to its relative chemoresistance. The overall clinical response in 
chemotherapy-treated patients with recurrent OCCC is only 25-40%. Therefore, the investigation 
and development of new compounds is necessary to overcome the high rates of drug resistance 
in OCCC. Our results indicate high levels of expression of phosphorylated STAT3 
(pSTAT3Tyr705 and Ser727) in ovarian clear cell carcinoma (OCCC), which may prove to be an 
important chemo-resistant pathway for OCCC.  
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Abstract 
Advanced ovarian clear cell carcinoma (OCCC) carries a very poor prognosis in large part 
secondary to the extremely high rate of resistance to standard platinum and taxane 
chemotherapy.  STAT3 expression and activation has been shown to regulate tumor progression 
in various human cancers, though has not been well studied in OCCC.   Preliminary work in our 
lab has demonstrated constitutive activation of STAT3 (pSTAT3Tyr705 or pSTAT3727) in 
OCCC cell lines as well as human OCCC tumor tissue samples. Significantly, pSTAT3 is 
expressed in the absence of other forms of activated STAT (pSTAT1, 2, 6).  Therefore, this work 
was planned to investigate the role of STAT3 and examine the efficacy of a novel anti-cancer 
compound -HO-3867, which is an inhibitor of STAT3, using known OCCC cell lines.  Results 
demonstrate that treatment with HO-3867 decreased expression of pSTAT3 Tyr705 as well 
pSTAT3 Ser727, while total STAT3 remained constant. STAT3 overexpression increased the 
migration capability in OVTOKO cells in vitro and led to an increased tumor size when injected 
in vivo. The inhibitory effect of HO-3867 on cell proliferation and cell survival was accompanied 
by increased apoptosis, within 24 h post treatment. Treatment with HO-3867 resulted in a 
decrease in Bcl-2 and increase of cleavage of caspase 3, caspase 7, and PARP, confirming 
induction of apoptosis after treatment with HO-3867.  In addition, HO-3867 significantly 
inhibited formation of HUVEC cells capillary-like structures and invasion at both 5 and 10µM 
concentrations. STAT3 expression plays an important role in the spread of OCCC in vitro as well 
as in vivo. Thus, we can exploit the STAT3 pathway for targeted drug therapy. Inhibition of 
pSTAT3 using HO-3867in OCCC cell lines appears to be a promising therapy.  This is of utmost 
importance given the poor response of OCCC to standard chemotherapy regimens.    
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Introduction 
Ovarian clear cell carcinoma (OCCC) accounts for approximately 5 to 25% of epithelial ovarian 
cancers with varying incidence by population
1-3
. Though rare, it presents a unique treatment 
challenge.  While OCCC tends to present at earlier stages, women with advanced disease have a 
poor prognosis compared with other epithelial ovarian cancer (EOC) subtypes
3-5
.  This is 
illustrated by a meta-analysis of multiple clinical trials of advanced-stage EOC that noted a 
median overall survival of 21.3 months for women with OCCC, compared to 40.8 months for 
those with high grade serous ovarian cancer (HGSOC)
5
. It has been hypothesized that the 
discrepancy in outcomes may be at least in part secondary to tumor resistance to chemotherapy. 
While platinum-based chemotherapy is standard first-line treatment for EOC, OCCC does not 
respond well to the regimen. In a multi-center retrospective study of patients with stage III/IV 
OCCC with measurable disease after surgery, response to platinum-based chemotherapy was 
11.1%, as compared to 72.5% in patients with HGSOC 
4
.  Another analysis of data from multiple 
clinical trials for advanced ovarian cancer found that overall response rates were 45% for OCCC 
versus 81% for HGSOC
6, 7
.  
            While the relative chemoresistance of OCCC is felt to portend a worse prognosis, the 
precise mechanism of resistance remains unclear. Thus, to improve outcomes for patients 
diagnosed with OCCC, it is critical to find ways to overcome chemoresistance or identify new 
targets for therapy.  Signal transducer and activator of transcription 3 (STAT3) is a transcription 
factor that mediates cytokine and growth factor signaling.  STAT3 activation contributes to 
tumorigenesis by promoting cell proliferation, survival, angiogenesis, metastasis, inflammation, 
and immune evasion 
8-11
.  STAT3 expression and activation has been shown to regulate tumor 
progression in various human cancers including HGSOC, though has not been well studied in 
OCCC.  OCCC is characterized by a high rate of ARID1A and PI3K mutations which have been 
shown to cooperate in animal models to promote OCCC tumor growth through sustained IL-6 
overproduction leading to increased activation of STAT3
12
. Additionally, Anglesio et al 
demonstrated overexpression of IL6-STAT3-HIF pathway in OCCC
13
. These findings support 
further investigation into STAT3 as a potential therapeutic target in OCCC. 
We have previously shown that activation of STAT3 is necessary for HGSOC tumor 
progression/metastasis and targeting STAT3 with HO-3867 (a member of a novel class of anti-
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cancer drugs, diarylipenylpiperiden-4-ones (DAP’s) significantly suppressed tumor growth and 
metastasis
10, 14-16
.  Therefore, this study was designed i) to investigate and establish the role of 
STAT3 in OCCC progression in OCCC cells and human OCCC patient tissue samples ii) to 
examine the efficacy of our STAT3 inhibitor, HO-3867 in vitro and in vivo using the orthotopic 
tumor model.      
Material and Methods 
Culture of OCCC cells: The OCCC cell lines OVTOKO, JHOC, OVISE and ES2 were a kind 
gift from Ikuo Konishi, Kyoto Medical University, Japan. The cells were cultured in T75 flasks 
in RPMI medium supplemented with FBS (10%) and Penicillin/ streptomycin (1%).  
Immunocytochemistry: Cells in RPMI medium were seeded onto sterile glass coverslips in 6-
well plates with an average population of 50,000 cells/well.  After 24 hours of culture, the cells 
were washed, fixed, and incubated with primary antibody according to a previously described 
protocol. 
STAT3 overexpression/knockdown experiments: For downregulation of STAT3 in OVTOKO 
cells, a lentiviral system with a set of different short hairpin RNAs (shRNA) was used (Stat3 
shRNA (h) Lentiviral Particles, Santa Cruz Biotechnology, Texas, USA) using Dharmafect 
Transfection Reagent (GE, Lafayette, CO) in OVTOKO cells.  For STAT3 overexpression, we 
used EF.STAT3C.UbC.GFP, which was a gift from Linzhao Cheng (Addgene plasmid#24983), 
transfected into OVTOKO cells using Dharmafect Transfection Reagent (GE, Lafayette, CO). 
Immunoblot analysis: Cells in were treated with HO-3867 (5 µM or 10 µM) for 24 hours. 
Following treatment, the cell lysates were prepared in non-denaturing lysis buffer as previously 
described 
17
. 
Cell migration Assay: Cell migration assays were performed on both treated and non-treated 
cells using a wound-healing method 
18
.  
RNA isolation and Reverse Transcription PCR (RT PCR): OVTOKO cells were counted and 
plated in equal numbers in petridishes. The petridishes were treated with HO-3867 at 5 and 
10µM concentrations, with at least 3 plates per treatment. At 24 hours post treatment, the cells 
were collected and stored in the -80°C until further use. Total RNA was isolated using the 
RNeasy Mini Kit (Qiagen, Valencia, CA). RNA samples with an optical density A260/A280 
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ratio between 1.8 and 2.1 were used. RT‐PCR was then performed using the Transcriptor First 
Strand Complementary DNA (cDNA) Synthesis Kit (Roche Applied Science) to synthesis 
cDNA. RT‐PCR was performed with 1mg of RNA template. The reaction was carried out using 
the Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA) and random hexamer primers. 
Quantitative Real Time PCR (qPCR): The genes studied for their relative genetic expression 
patterns are provided in Table 1. LightCycler 480 SYBR Green I Master Mix (Roche Applied 
Science) was used to analyze 100 ng of cDNA from each experimental condition along with their 
respective primers (Table I).  qRT‐PCR was performed using the Light Cycler 480 System 
(Roche Applied Science). Each sample was normalized to the control gene glyceraldehyde 
3‐phosphate dehydrogenase (GAPDH. 
STAT3 DNA-binding assays: After treatment with HO3867 for 24 hours, a nuclear extract kit 
(Clontech Inc., Mountain View, CA) was used to prepare cell nuclear extracts following the 
manufacturer's protocol. Nuclear extracts were analyzed for STAT3 DNA binding activity using 
the TransFactor Universal STAT3-specific kits (Clontech Inc., Mountain View, CA) with an 
ELISA-based method. 
Ubiquitin assay: To trace the ubiquitinated proteins in the cell lysates, agarose beads coated 
with domains having affinity to ubiquitin were incubated in the lysates at 4°C for 2 hours. After 
washing the beads, the ubiquitinated proteins were subjected to immunoblot for pSTAT3 and 
blotted by the ubiquitin antibody
19
.  
Evaluate the bio-absorption of DAPs in ovarian cancer cells using EPR: Our previous study 
showed that cellular uptake of HO-3867 was significantly greater than curcumin 
20
. We 
evaluated the bio absorption of HO-3867 compounds in ES2 and OVTOKO cells after 1, 3 , and 
6 hrs post treatment, using EPR, as previously described 
21
. 
Development of orthotopic tumor model 
STAT3 overexpression OCC cells (3 × 10
*6
 cells in 100 µL of PBS) were injected into the 
ovarian bursa of 6-week-old BALB/c nude mice from the OSU Transgenic mice core lab. In vivo 
MRI imaging was done periodically to check upon the tumor growth.  After sacrifice, the tumor 
weight and volume was measured. 
Statistical Analysis 
Data are presented as mean+1 standard deviation 
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RESULTS 
Validate the expression of STAT3 in OCCC cell lines and human patient tissue samples 
We received 7 OCCC tissue samples from consented patients with OCCC at our institution and 
analyzed the expression of pSTAT3 Tyr705, pSTAT3 Ser727 and total STAT3. Five out of 7 
samples showed moderate to high expression of pSTAT3Tyr705 on Western Blot (Fig. 1A). 
Expression was tested in OCCC cell lines (JHOC and OVTOKO) that were gifted by Dr. Konishi 
at Kyoto University for the current study. The studied cell lines showed moderate to high 
expression of pSTAT3 Tyr705, Ser727 and total STAT3, when analyzed by western blot (Fig. 
1B). pSTAT3 Tyr705 showed high expressions in all tested cell lines (Fig. 1B). OVTOKO cells 
(90-95%) showed pSTAT3 Tyr705 localized in the nucleus as well as the cytoplasm while 
pSTAT3 Ser727 was mostly found in the cytoplasm of OVTOKO cells (Fig. 1C).  
Effect of STAT3 overexpression or knockdown in ovarian clear cell carcinoma cells in vitro 
as well as in vivo. 
In our previous studies with HGSOC, we found that the knockdown of STAT3 causes reduction 
in tumor growth and metastases in vivo
10
.  Based on this finding, we considered it imperative to 
determine if STAT3 plays a role in cell proliferation, migration, and survival OCCC cell lines as 
well. Therefore, we developed OVTOKO STAT3 overexpression (STAT3 OE) cells by 
transfecting OVTOKO cells with a plasmid construct constitutively expressing pSTAT3 Tyr705. 
Fig. 2A shows the western blot expression of pSTAT3 Tyr705 in 4 of the tested OE clones. We 
found that clone O6 showed the highest expression of pSTAT3 Tyr705 so we moved forward 
with this clone for our future studies. Additionally we used siRNA for STAT3 to knockdown 
STAT3 from the OVTOKO cells, which was confirmed by western blot (Fig. 2B & C). Since an 
increased STAT3 expression is known to cause extensive migration as well as invasion
10, 22
 , we 
analyzed the changes in the wound closure behavior of the cells. To confirm this, we performed a 
wound healing assay, where a monolayer of cells growing on a petri dish were scratched 
uniformly and observed at 24 hours for their ability to repair the damaged area for the control 
OVTOKO cells, OVTOKO STAT3 OE as well as OVTOKO STAT3 KO cells. The control 
OVTOKO and OVTOKO STAT3 OE cells migrated at about the same rate in the first 24 hours. 
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However, OVTOKO STAT3 KO cells migrated to approximately 20 to 30% of the wounded 
area (Fig. 2D & E).  
This was further confirmed at the mRNA level using real time quantitative PCR to check the 
relative expression of genes related to angiogenesis, cell survival and cell proliferation. The 
relative mRNA expression of STAT3 was highest in OVTOKO STAT3 OE cells followed by the 
control OVTOKO cells and OVTOKO STAT3 KO cells (Fig. 2F). The STAT3 target genes like 
Survivin, VEGF, c-myc and BCl2 were highest in the OVTOKO STAT3 OE cells and least in 
the OVTOKO STAT3 KO cells (Fig. 2F). Taken together, these results suggest that deleting 
STAT3 inhibits the expression of a number of genes responsible for cell survival, proliferation 
and angiogenesis. These findings were further evaluated in vivo.  The OVTOKO control and 
OVTOKO STAT3 OE cells were injected into the right ovarian bursal cavity of nude mice (Fig. 
2G). It is noteworthy that the mice injected with control OVTOKO cells failed to develop any 
primary tumor in the first 5 weeks post inoculation. However, the mice injected with OVTOKO 
STAT3 OE cells developed significantly large tumors as demonstrated in Fig.2H. No metastases 
were observed in any of the cases.  These results add support to the role of STAT3 in OCCC 
tumor development and growth, and its ability to regulate the expression of different genes 
involved in survival and proliferation.     
HO-3867 targets on STAT3 and its associated genes in OCCC cells  
We used OVTOKO and JHOC cell lines to test the therapeutic efficacy of our previously 
developed novel DAP compound on OCCC cell lines. We treated the OVTOKO and JHOC with 
2 different concentrations (5 and 10µM) of HO-3867. Western blot expression in Fig. 3A clearly 
shows that the expression levels of both pSTAT Tyr705 and pSTAT Ser727 drastically decreases 
even in the lowest dose of 5 µM and is almost non-existent in the higher dose of 10µM for both 
the tested OCCC cell lines (Fig. 3B). To determine whether HO-3867 inhibited pSTAT3 DNA 
binding activity, OVTOKO and JHOC cells were treated with 10µM of HO- 3867, and samples 
were subjected to ELISA assay. HO-3867 compound inhibited STAT3 DNA binding activity in 
both cells when compared with control (Fig. 3C). Further, the STAT3 regulated genes like 
JAK1, Tyk2 and CDK5 also showed a diminished expression post treatment with HO-3867 for 
both the tested OCCC cell lines. MCL1, BCl2, Cyclin D2 and c-myc were also decreased post 
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HO-3867 treatment for both JHOC and OVTOKO cells (Fig. 3D&E). This demonstrates that 
HO-3867 effectively targets STAT3 and its associated genes in OCCC cells.  We sought to 
confirm these findings at the level of relative mRNA expression using qRT-PCR. The RNA 
obtained from the treated OVTOKO cells was converted to cDNA and subjected to real time 
PCR using the gene specific primers for STAT3, JAK1, BCl2, c-myc and cyclin D1. We found 
that mRNA expression for STAT3 and JAK1 was decreased post treatment with HO-3867 at 
both the doses of 5 & 10uM. However, the expression levels of BCl2, c-myc and cyclin D1 were 
not significantly decreased after treatment with HO-3867 (Fig. 3F).   
 
Ubiquitination is the first step of the ubiquitin-proteasome pathway that regulates cells for their 
homeostatic functions and is an enzymatic, protein post-translational modification process in 
which ubiquitin is transferred to a target protein substrate by a set of three ubiquitin enzymes
23-25
. 
Given the importance of this process, it is plausible that HO-3867 has a function to regulate the 
ubiquitination. Therefore, we examined the ubiquitination status of the OVTOKO cells post 
treatment with HO-3867 and observed an enhanced degradation in both OVTOKO and JHOC 
cells post treatment for both the concentrations. Further, the degradation was concentration 
specific and increased with the increasing dosage of HO-3867 (Fig. 3G).  
HO-3867 inhibits cell survival and increase the caspase cascade pathway 
To evaluate the effect of HO-3867 on OCCC survival, we treated cells with different 
concentrations (1, 2.5, 5, 10 and 20 uM) of HO-3867 at time points (24 and 48 h). Cell viability 
was measured by MTT assay and cell count. The proliferation and survival of OCCC cells were 
inhibited by HO-3867 in a dose-dependent manner (Fig. 4A). Caspases are aspartic acid-specific 
proteases and are the major effectors of apoptosis. Therefore, in order to confirm if the activity of 
HO-3867 also activates the caspase cascade, we performed western blot on OVTOKO, ES-2, 
OVISE and JHOC cells and found that PARP, cleaved caspase 3 and cleaved caspase 9 were all 
upregulated post treatment with HO-3867 (Fig. 4B). As an additional proof of concept 
experiment, we further studied the caspases in ES2 and OVISE cells and found that the higher 
dose of 20 µM was able to activate cleaved caspase 3 and cleaved caspase 7 and PARP was 
activated even by the lower dose of 10 µM (Fig. 4B). This was further confirmed by Annexin V 
staining assays using a flow cytometer. It is known that in early stages of apoptosis, the plasma 
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membrane excludes viability dyes such as propidium iodide (PI) and display only Annexin V 
staining. We observed an increase in the percent of Annexin V positive cells post treatment with 
30 to 51% of apoptotic cells post treatment as compared to 5 to 10 % cells undergoing apoptosis 
in the untreated cells (Fig. 4C&D). The HO-3867-treated STAT3-overexpressing cells showed 
increase cell proliferation and decrease apoptotic proteins, in comparison with HO-3867 alone 
treated cells (Fig. 4E & F), suggesting that HO-3867 might target, at least in part, STAT3 in 
OCCC. EPR spectrum obtained from ovarian clear cell carcinma showing the presence on HO-
3867 in the oxidized (nitroxide) form. HO-3867 levels in the cells samples were determined 
using EPR, clear, triplet signals indicating the presence of the –NO_ radical (nitroxide) form of 
HO-3867 were obtained from both cell lines and quantified (Fig. 4G & H).  
Effect of HO3867 on human endothelial (HUVEC) cells 
In the ovarian clear cell tumor microenvironment, tumor cells secrete VEGF and other 
angiogenic factors that promote the growth and assembly of neighboring endothelial cells. Since 
HO-3867 can block secretion of important angiogenic proteins, we next examined if HO3867 
treatment suppresses the growth and differentiation of human umbilical vein endothelial cells 
(HUVEC) in response to treatment with VEGF. HO-3867 significantly inhibited formation of 
capillary-like structures at both 5 and 10µM concentrations (Fig. 5A), indicating that signaling 
through STAT3 is necessary for VEGF-stimulated proliferation and tube formation of these 
endothelial cells. A 3D angiogenesis model utilizing VEGF stimulated HUVEC spheroids 
embedded in a collagen matrix recapitulates the inhibition of tube-like formation by HO3867 
seen in the two-dimensional model.  After successful stimulation, new blood vessels sprouted 
into the collagen matrix within 2-3 days and were quantified in the presence and absence of 
HO3867. Fewer number and shorter length of the sprouts demonstrates the anti-angiogenic 
activity of HO3867 in comparison to the control group (Fig. 5B).  HO3867 treatment also 
significantly blocked the invasion of VEGF-stimulated HUVECs through a Boyden chamber 
(Fig. 5C).  
Cytosolic STAT3 is known to be a co-regulator of F-actin fiber 
26
 and microtubule 
27
 
formation. The disruption of lamellipodia formation and microtubule breakdown at the trailing 
edge may explain the drastically reduced invasion of HUVEC cells. In order to confirm this, 
HUVEC cultures were treated with VEGF alone, VEGF plus DMSO (drug vehicle) or VEGF 
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with HO-3867 for 18 hrs followed by staining for F-actin and b-tubulin. (Fig. 5D). Thin, uniform 
fibers spanning the length of the cells were characteristic of the F-actin in the control and VEGF-
treated cultures, with greater localization at the peripheral lamellipodia and intercellular 
junctions. The microtubules extended to the periphery of the cells forming a dense lattice that 
emanated from the center of the cells. However, in STAT3 inhibited cultures, the cells displayed 
a condensed and rounded morphology. The actin had condensed into fewer fibers, and most 
strikingly, was completely absent from the leading edges of the cells (white arrows, Fig. 5D). 
The microtubule structures were additionally affected by the HO-3867 treatment. As highlighted 
by the arrowheads in Figure 5D, tubulin staining still showed that the microtubules emanated 
from the nuclear region of the HUVEC cells, but at the periphery, they curled over. 
 
Discussion 
Our results indicate high levels of expression of phosphorylated STAT3 (pSTAT3Tyr705 
and Ser727) in ovarian clear cell carcinoma (OCCC) which may prove to be an important 
pathway for OCCC cell survival, proliferation, and angiogenesis. Further, this is the first report 
proving the efficacy of HO-3867, a curcumin analog, in inhibiting OCCC cell survival and 
proliferation; induction of apoptosis and inhibition of angiogenesis by targeting the activation of 
STAT3. 
Recent studies have identified potential driver genes and aberrant signaling pathways 
involved in development of OCCC 
7, 28, 29
. As described above, ARID1A and PI3K mutations are 
detected in more than 55% and 30% of OCCC cases respectively
2, 12
.  Co-existent ARID1A and 
PI3K mutations have been shown to promote OCCC tumor growth through overproduction of 
IL-6 and activation of STAT3 lending STAT3 an attractive target for therapy
12, 13
.  Although, the 
expression of STAT3 oncogene is well known in high grade serous ovarian cancer (HGSOC)
9, 10, 
30, 31
, moderately little is known about the STAT3 signaling pathways in OCCC; its involvement 
in chemo-resistance and poor survival or its potential as a therapeutic target. This study 
identified a) the expression of STAT3 in OCCC patient tissues and cell lines and  b) STAT3 
expression can up-regulate its target genes such as c-MYC (proliferation), and Bcl-2 (cell 
survival and anti-apoptotic) thus playing a key role in proliferation and tumor progression of 
OCCC. Recent studies in renal clear cell carcinoma have associated higher expression of 
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pSTAT3 with the tumor grade and poor patient survival
32, 33
. It is clearly evident from our study 
that the expression of STAT3 might affect patient survival in OCCC, and targeting STAT3 using 
small molecule inhibitors could possibly inhibit OCCC tumor growth and help overcome the 
chemotherapeutic resistance in OCCC tumors. 
We have recently reported four promising DAP compounds which are STAT3 inhibitors- 
H-4073, HO-3867, H-4318 and HO-4200
15, 16, 34
. HO-3867 demonstrate high cytotoxicity 
towards human ovarian cancer cells, including those known to be chemo-resistant, under both in 
vitro and in vivo conditions 
14
. We have selected one of our best DAP compound STAT3 
inhibitor-HO-3867, based on the STAT3 DNA binding activity and selective cytotoxicity in 
cancer cells rather than normal epithelial cells, for the current study. HO-3867 significantly 
inhibits pSTAT3 in OCCC cells, through the upstream pathways of STAT3 such as JAK and 
TYK2. In addition, the current study showed an enhanced poly-ubiquitination of pSTAT3 by 
HO-3867 treatment in OCCC. These results suggest that in OCCC, HO-3867 targets STAT3 
through dual pathways—the ubiquitin-dependent degradation of pSTAT3 and the inhibition of 
upstream regulators of pSTAT3, such as JAK1 and TYK2, eventually inhibiting cell proliferation 
and inducing apoptosis via modulating its target genes (Cyclin D1 and Bcl-2). 
Targeting angiogenesis and VEGF is another therapeutic approach used in treatment of 
several solid tumors, OCCC included 
13, 35
. VEGF was reported to be strongly expressed in 
OCCC cells and patient samples, both in early- and advanced-stage disease. High levels of 
VEGF expression are additionally associated with shorter survival than those with lower levels 
of VEGF expression in OCCC
6, 35
. In this study, we document direct effect of HO-3867, by 
suppressing HUVEC cell migration/ invasion, tube formation of endothelial cells and affecting 
the microtubule structures. This proves that STAT3 signaling closely governs these processes 
and affect STAT3 downregulated protein - VEGF in OCCC. Further, clinical evidence showed 
that sunitinib, a potent VEGF inhibitor, is more responsive in the treatment of clear cell 
carcinoma patients than serous tumors
6, 36, 37
.  
In conclusion, we demonstrate that pSTAT3 expression is highly elevated in OCCC 
tumors and is a potential therapeutic target for this disease. Our small molecule STAT3 inhibitor 
of HO-3867 efficiently inhibits pSTAT3 and its target proteins, thereby impeding cell 
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proliferation, angiogenesis and cytotoxicity in OCCC and seems promising in the future 
treatment of ovarian clear cell carcinoma. 
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Figure Legends 
Fig. 1: Validation of the expression of STAT3 in OCCC cell lines and human patient tissue 
samples. A: Western blot for Human OCCC tumor samples obtained from 7 consented OCCC 
patients. Th  extracted proteins blotted on a PVDF membrane were probed for pSTAT3 Tyr705 
(topmost), pSTAT3 Ser727 (middle lane), total STAT3 (lower lane). All the samples show a 
medium to high pSTAT3 Tyr705 expression except for patient no. 3 and 7. All the patients 
showed pSTAT3 Ser727 and total STAT3 expression.  B: Western blot results for human OCCC 
cell lines-JHOC (J), and OVTOKO (OV). Both cell lines showed a high range of expression of 
pSTAT3 Tyr705 and pSTAT3 Ser727 (highly elevated in OV) and total STAT3. C: 
Immunocytochemistry (ICC) of OCCC cell line OVTOKO with pSTAT3 Tyr705 (left 2 in the 
row) which is mostly nuclear and pSTAT3 Ser727 (right 2) which is predominantly cytoplasmic.  
Fig. 2: Effect of STAT3 overexpression or knockdown in ovarian clear cell carcinoma cells in 
vitro as well as in vivo. A: Confirmation of STAT3 overexpression in OVTOKO cells using a 
Western Blot where N is control OVTOKO, O1, O3, O5 and O6 are overexpression clones 1,3,5 
and 6. The bottom panel is β-actin expression as loading controls. In order to create STAT3 
overexpression cells, OVTOKO cells were transfected with a vector harboring STAT3 gene or 
with the empty vector backbone for control. Based on the strongest expression in clone O6, we 
proceeded with this clone for all our future studies. B & C: OVTOKO cells were transfected 
with STAT3 shRNA and the knockdown was confirmed by western blot analysis and RT-PCR. 
Knockdown of pSTAT3 705 in OVTOKO cells is clearly evident. D: OVTOKO cells with 
STAT3 overexpression and STAT3 knockdown were subjected to wound healing assays in order 
to understand the correlation between STAT3 expression level and migration capability in 
OVTOKO cells. The panel on the left shows the plates at 0 hr after scratch and the panel on the 
right show the migration pattern after 24 hours. The cells over-expressing STAT3 migrate and 
close the gap within the first 24 hours (top and middle picture on the right panel) while the 
STAT3 knockdown cells (bottom left) migrate to fill 65-70% of the scratched area. E: The 
percentage of migration was quantified using Image J software in 0h, 24h compared with STAT3 
OE and siRNA experiments; F: Real time quantitative PCR was performed for the relative 
mRNA expression of STAT3 in OVTOKO control, OVTOKO STAT3 OE and OVTOKO 
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STAT3 Ko cells. The values were calculated using the 2(-Delta Delta C(T)) method and were 
normalized to the housekeeping gene GAPDH. Each experiment was repeated thrice and each 
sample had 4 replicates. The horizontal line over the bars indicates that the results are significant 
with a p value < 0.005.RT. RT-qPCR of OVTOKO, OV STAT3 Si and OVTOKO STAT3 OE 
cells for STAT3 and regulatory genes- survivin, VEGF, c-myc and BCl2. The very high relative 
mRNA expression was observed in OVTOKO STAT3 OE cells for all the studied genes. G: The 
panel shows orthotopic mice injected with OVTOKO control and OVTOKO STAT3 
overexpression cells. Mouse injected with OVTOKO STAT3 OE cells developed a big tumor in 
4 weeks post inoculation but no tumor could be seen in the OVTOKO control mice. Some of the 
mice injected with control OVTOKO cells, which were left for 3 months, developed a noticeable 
tumor; H: The weight of the ovarian tumor was significantly higher in the STAT3 OE 
transfected OV cells transplanted mice when compared to the OV cells transplanted mice. 
Fig. 3: HO-3867 targets STAT3 and its associated genes in OCCC cells. A: Western blot of 
proteins extracted from OCCC cells with/without treatment with HO-3867 at 5 or 10µM 
concentrations of HO-3867. The membrane was blotted for pSTAT3 705 (1
st
 row), pSTAT3 727 
(2
nd
 row), total STAT3 (3
rd
 row) and β-actin (4
th
 row) for OVTOKO (left column) and JHOC 
cells (right column). B: quantitative results of pSTAT3 Tyr705 bands by densitometry analysis 
in HO-3867 treated cells. C: HO-3867 inhibit DNA-binding of STAT3, as indicated by ELISA 
assay results. D: Western blot for genes associated with STAT3 upstream. The membrane was 
blotted for JAK1 (1
st
 row), TYK2 (2
nd
 row), ERK 1/2 (3
rd
 row), CDK5 (4
th
 row) for OVTOKO 
(left column) and JHOC cells (right column).  E: Western blot for genes associated with STAT3 
downstream.  The membrane was blotted for MCL1 (1
st
 row), BCl2 (2
nd
 row), cyclin D2 (3
rd
 
row) and c-myc (4
th
 row) for OVTOKO (left column) and JHOC cells (right column).  F: RT-
qPCR of OVTOKO cells post treatment with HO-3867, with primers specific for STAT3 and 
regulatory genes- JAK1, BCl2, c-myc and cyclin D1. G: ubiquitination status of the OVTOKO 
(left panel) and JHOC (right panel) cells post treatment with HO-3867. Increased degradation in 
both OVTOKO and JHOC cells post treatment for both the concentrations. 
 
Fig. 4: The survival-inhibitory effect of HO-3867 on OCCC. A: The cell number was counted at 
days 1, & 2 after HO-3867 incubated. A dosage- dependent inhibition of cell survival is shown. 
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Cell viability assay in HO-3867 treated OCCC. OCCC were seeded on a 6 well plate, and 
incubated with each concentration of HO-3867 up to 2days. Activation of the caspase cascade 
pathway by HO-3867. B: Western blot of proteins extracted from OCCC cells with/without 
treatment with HO-3867 at 5 or 10µM concentrations of HO-3867. The membrane was blotted 
for PARP (1
st
 row), cleaved caspase 3 (2
nd
 row), cleaved caspase 7 (3
rd
 row) and β-actin (4
th
 row) 
for OVTOKO (left column) and JHOC cells (right column). C: Cytograms obtained from 
Annexin V assays of HO-3867 (10 µM) -treated OVTOKO (bottom row) and JHOC (top row) 
cells. Each cytogram consists of data showing live cells (PI and FITC negative) bottom left; early 
apoptotic population (FITC positive) bottom right; mid-late stage apoptosis (PI and FITC 
positive) top left; necrotic/end stage apoptotic cells (PI positive, FITC negative) top right. Left 
column: control untreated cells; Right column: HO-3867-treated cells. The live cell population is 
indicated for each sample and is representative of typical data obtained. D: Data shown are 
representative of triplicate experiments and the numbers refer to the mean (and standard 
deviation) live (PI and FITC negative) populations (expressed as a percentage of the untreated 
controls). E: STAT3 OE transfected OCC cells are resistant to HO-3867 10uM treatment. F: The 
STAT3 plasmid gene was transiently transfected into OV cells. At 24 hours after the transfection 
of the STAT3 gene, HO-3867 10uM was added into the culture medium of the cells. The 
untransfected cells with vehicle (DMSO) alone, the untransfected cells with the HO-
3867exposure. The STAT3 gene–transfected OV cells inhibit the HO-3867-induced cleavages of 
caspase-3, -7 and PARP. G & H: Cellular absorption of HO-3867 10uM using electron 
paramagnetic resonance (EPR) spectrometry to quantify the intracellular content of HO-3867 in 
various time points in OVTOKO and ES2 OCCC cell lines. Results showed that HO-3867 
rapidly entered the cells within the 1st hour of treatment period. 
 
Fig. 5: Inhibition of angiogenesis by HO-3867 correlates with inhibition of STAT3 
phosphorylation. A: Suppression of angiogenesis formation by HO-3867 in HUVEC cells after 
VEGF (10 ng/ml) stimulation. HUVEC cells were grown and stimulated with VEGF (10 ng/ml) 
for 10 min and treated with HO-3867 for 6 and 12hrs. B: 3D-Angiogenesis Assay (PromoCell) 
which demonstrates the entire angiogenesis process in vitro – proteolytic activity, migration, 
proliferation, and lumen formation. The number and length of the sprouts demonstrates the  anti-
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angiogenicity of HO-3867 in comparison to the control group. HO-3867 inhibits HUVEC tube 
formation. HUVECs were grown in M200, and incubated with PBS or VEGF (10 ng/ml) for 18–
20 hr in the absence or presence of HO-3867 (10µM). Tube formation was quantified (bottom 
right panel) as described in Materials and Methods. C: Invasion was determined using Matrigel 
coated membranes (photomicrographs show representative fields). Each data set represents the 
mean SE for at least 3 independent experiments. D: The STAT3 inhibitor, HO-3867, induces 
cytoskeletal changes in cultured HUVEC cells. HUVEC cells cultured in 4-well chamber slides 
were treated with PBS, VEGF (10 ng/mL) alone, VEGF with DMSO or HO-3867 (10 µM) for 
18 hrs. The cultures were then probed using anti-β tubulin primary antibodies (green), and F-
actin was stained using phalloidin (red). White arrows highlight F-actin localization at the 
leading edge, while white arrowheads indicate the curling of microtubules at the cell periphery. 
2006magnification. Slice depth = 1 mm. Scale bar = 20 mm. Inset 400magnification. 
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